Related references
Note: Only part of the references are listed.End-of-treatment but not interim PET scan predicts outcome in nonbulky limited-stage Hodgkin's lymphoma
J. A. Barnes et al.
ANNALS OF ONCOLOGY (2011)
Doxorubicin, vinblastine, and gemcitabine (CALGB 50203) for stage I/II nonbulky Hodgkin lymphoma: pretreatment prognostic factors and interim PET
David J. Straus et al.
BLOOD (2011)
Concordance between four European centres of PET reporting criteria designed for use in multicentre trials in Hodgkin lymphoma
Sally F. Barrington et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2010)
The Present: Optimizing Therapy-Too Much or Too Little?
Nancy L. Bartlett
HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM (2010)
Prognostic significance of mid- and post-ABVD PET imaging in Hodgkin's lymphoma: the importance of involved-field radiotherapy
D. J. Sher et al.
ANNALS OF ONCOLOGY (2009)
Fluorine-18-Fluorodeoxyglucose Positron Emission Tomography for Interim Response Assessment of Advanced-Stage Hodgkin's Lymphoma and Diffuse Large B-Cell Lymphoma: A Systematic Review
Teruhiko Terasawa et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Early relapse in a patient with Hodgkin's disease and negative interim FDG-PET
Stefano Fanti et al.
ANNALS OF NUCLEAR MEDICINE (2008)
Blinded independent central review of progression-free survival in phase III clinical trials: Important design element or unnecessary expense?
Lori E. Dodd et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Early interim PET scan in Hodgkin lymphoma: Where do we stand?
Andrea Gallamini et al.
LEUKEMIA & LYMPHOMA (2008)
Early interim 2-[18F]Fluoro-2-Deoxy-D-Glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma:: A report from a joint Italian-Danish study
Andrea Gallamini et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Cost-effective therapy remission assessment in lymphoma patients using 2-[fluorine-18]fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography: is an end of treatment exam necessary in all patients?
K. Strobel et al.
ANNALS OF ONCOLOGY (2007)
Revised response criteria for malignant lymphoma
Bruce D. Cheson et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Early FDG-PET assessment in combination with clinical risk scores determines prognosis in recurring lymphoma
Bart W. Schot et al.
BLOOD (2007)
FDG-PET/CT predicts outcome in patients with aggressive non-Hodgkin's lymphoma and Hodgkin's disease
Solene Querellou et al.
ANNALS OF HEMATOLOGY (2006)
Early positron emission tomography (PET) restaging: a predictive final response in Hodgkin's disease patients
P. L. Zinzani et al.
ANNALS OF ONCOLOGY (2006)
Tumor microenvironment and mitotic checkpoint are key factors in the outcome of classic Hodgkin lymphoma
Abel Sanchez-Aguilera et al.
BLOOD (2006)
FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma
M Hutchings et al.
BLOOD (2006)
Prognostic value of interim FDG-PET after two or three cycles of chemotherapy in Hodgkin lymphoma
M Hutchings et al.
ANNALS OF ONCOLOGY (2005)
Early therapy monitoring with FDG-PET in aggressive non-Hodgkin's lymphoma and Hodgkin's lymphoma
T Torizuka et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2004)
The clinical value of tumor burden at diagnosis in Hodgkin lymphoma
PG Gobbi et al.
CANCER (2004)
[18F]FDG PET monitoring of tumour response to chemotherapy:: does [18F]FDG uptake correlate with the viable tumour cell fraction?
K Spaepen et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2003)